Notably, on day 12 after the injection of tumor cells, PARPi reduced the growth of TRDMT1-depleted tumors more than control tumors (70% vs. 45%) (Fig. 5d), suggesting that loss of TRDMT1 increases the HR deficiency in tumor cells. This evidence concerns the gene TRDMT1 and neoplasm.